Nanotechnology is transforming autoimmune disease treatment by enabling precise targeting, reducing systemic toxicity, and promoting immune tolerance.
Traditional therapies rely on broad immunosuppression, leading to serious side effects like osteoporosis, hypertension, and increased infection risk. New nanomedicine platforms-including drug-loaded nanoparticles, CRISPR delivery systems, and stimuli-responsive carriers-offer targeted delivery to affected tissues.
Preclinical studies show promise: methotrexate-loaded nanoparticles reduced rheumatoid arthritis severity, while gluten-carrying PLGA nanoparticles induced tolerance in celiac disease patients.
Despite these advances, challenges remain in scalability, long-term safety, and regulatory approval. The future lies in integrating nanotherapeutics with personalized medicine for tailored immune modulation.